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Aim: Up-regulation of soluble CD40 ligand (sCD40L) and of monocyte chemoattractant protein-1 
(MCP-1) has been found in diabetes and in patients with acute cerebral ischemia. We asked whether (i) 
the two molecules are similarly upregulated among non-lacunar and lacunar diabetic strokes and (ii) 
sCD40L and/or MCP-1 predict the risk of cardiovascular events in this setting.
Methods: Ninety patients with type 2 diabetes mellitus presenting with an acute ischemic stroke 
(compared with 45 control subjects) were evaluated on admission and up to 36 months (median 24 
months) after the event.
Results: Diabetic patients with acute stroke had higher plasma CD40L and MCP-1 than controls (p＜
0.0001), with no significant differences among lacunar and non-lacunar strokes. On multiple regres-
sion analysis, only higher sCD40L quartiles and older age were associated with higher MCP-1 quar-
tiles. Forty-eight percent of patients experienced vascular events. Cox regression analysis showed that 
only the presence of higher sCD40L values independently predicted the recurrence of vascular events.
Conclusion: Up-regulation of inflammatory molecules, such as CD40L and MCP-1, is involved in 
the advanced stage of atherosclerotic cerebro-vascular disease and is associated with increased risk of 
recurrence of cardiovascular events.
J Atheroscler Thromb, 2009; 16:707-713.
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Cytokines and cytokine-inducible inflammatory 
molecules are regarded as predictive markers of cardio-
vascular events7). It is known that CD40 signaling 
mediates many inflammatory responses in athero-
sclerosis8). Enhanced CD40 ligand (CD40L) release is 
associated with thromboxane-dependent platelet acti-
vation in type 2 diabetes9). Activated platelets induce 
monocyte chemoattractant protein-1 (MCP-1) release 
from endothelial cells in a CD40L-dependent man-
ner10). MCP-1 is a chemokine responsible for the 
recruitment of monocytes to inflammation sites and 
its expression level is directly related to the extent of 
atherosclerosis and macrophage infiltration into the 
atherosclerotic lesion11). MCP-1 levels are increased in 
type 2 diabetes and are associated with increased risk 
of cardiovascular mortality12). Upregulation of soluble 
Introduction
Diabetes is a major risk factor for stroke1, 2) and 
is associated with an increase in overall stroke mortal-
ity attributable to higher-than-optimum blood glucose 
concentration3). Admitted patients with diabetes mel-
litus show a higher prevalence of lacunar stroke sub-
type than non-diabetics4). Whether lacunar strokes 
are associated with a different outcome vs non-lacunar 
strokes in diabetics is controversial5, 6).
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CD40L (sCD40L) and MCP-1 has been found in 
patients with acute cerebral ischemia, even though 
only 22% of patients with stroke or transient ischemic 
attack were diabetics13).
We asked whether, in a cohort of diabetic subjects 
with acute ischemic stroke (i) the two molecules are 
similarly up-regulated among non-lacunar and lacunar 
strokes and (ii) CD40L and/or MCP-1 may predict 
the risk of cardiovascular events in ischemic stroke.
Subjects
Between November 2002 and February 2006, 
we evaluated a cohort of 90 patients with type 2 dia-
betes mellitus, defined according to the World Health 
Organization diagnostic criteria for diabetes14) pre-
senting with an acute ischemic stroke, as diagnosed on 
the basis of neurological signs and symptoms and 
compatible CT findings, at the Department of Inter-
nal Medicine of Palermo University Hospital within 
72 hours after the onset of symptoms. Patients with 
symptoms lasting for ＞72 hours on admission were 
excluded from the study. Further exclusion criteria 
were acute and chronic inflammatory diseases, auto-
immune diseases or malignancies, acute coronary 
syndromes, intracerebral haemorrhage, and treatment 
with hormonal replacement therapy, steroids, and non-
steroidal anti-inflammatory drugs. A detailed history 
was obtained (Table 1).
Standard diagnostic tests included cranial com-
puted tomography to exclude intracerebral haemor-
rhage, duplex sonography to detect or exclude signifi-
cant stenosis of carotid arteries, and echocardiography 
to exclude the presence of an intracardiac thrombus.
Acute cerebral ischemias were classified according 
to the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) criteria15, 16). Severity of stroke was evalu-
ated by the Scandinavian Stroke Scale (SSS) score on 
Table 1. Clinical characteristics of patients and controls
Variable Patients, n =90 p value Controls, n =45
Age,＊ y
Sex,＊ F/M
TOAST
0
1
2
SSS Score
Plasma glucose on admission mmol/L (mg/dL)
HbA1c, %
Diabetes duration, yrs
BMI, kg/m
Hypertension,＊ n (%)
SBP, mmHg
DBP, mmHg
Total cholesterol, mmol/L (mg/dL)
Triglycerides, mmol/L (mg/dL)
Previous TIA,＊ n (%)
Previous stroke,＊ n (%)
Antiplatelet agents,＊ n, (%)
Lipid-lowering drugs,＊ n (%)
ACE-Ⅰ/ARBs,＊ n (%)
Body temperature, ℃
Leukocytes TSD/μL
sCD40L, Ü pg/mL
MCP-1, Ü pg/mL
72±10
39/51
36
41
13
37±10.2
12.5±3.4 (225±62)
7.7±1.6
9.5±3.9
30.7±1.7
55 (61)
153±16
92±20
5.9±1.0 (229±37)
2.1±1.3 (191±117)
46 (51)
38 (42)
42 (47)
24 (27)
61 (68)
37±0.5
8.5±2.1
1,252 (813−2,468)
210 (157−348)
0.89
0.90
－
－
－
－
＜0.0001
－
－
＜0.0001
＜0.01
＜0.0001
＜0.0001
＞0.05
＞0.05
＜0.001
＜0.001
＜0.001
0.16
＜0.001
－
＜0.0001
＜0.0001
＜0.0001
72±9
19/26
－
－
－
－
5.2±0.5 (94.5±7.9)
－
－
27.4±3.4
38 (84)
131±1.5
81±11
5.8±1.0 (226±38)
2.1±1.3 (186±106)
0 (0)
0 (0)
0 (0)
18 (40)
14 (31)
－
5.4±0.8
456 (326−650)
135 (85−198)
Data are the mean±SD, t test for independent samples. ＊Chi-square test. Ü Median (range), Mann-Whitney U test.
TOAST=Trial of Org 10172 in Acute Stroke Treatment, SSS=Scandinavian Stroke Scale, BMI=Body Mass Index, SBP= systolic 
blood pressure, DBP=diastolic blood pressure, ACE-Ⅰ=Angiotensin converting enzyme inhibitors, ARBs=Angiotensin receptor 
blockers, TSD= thousand, CD40L=CD40 ligand, MCP-1=Monocyte chemoattractant protein-1.
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acute admission17). SSS is an acute stroke assessment 
scale based on scored assessments of: level of conscious-
ness, eye movement, arm motor power, hand motor 
power, leg motor power, orientation, speech, facial 
palsy, and gait. Forty-five subjects (26 males and 19 
females, Table 1) were also recruited for the study as a 
control group. They were recruited from our vascular 
event prevention clinic and they were free of any pre-
vious vascular event. Controls were matched for sex 
and age with stroke patients. All patients gave written 
informed consent. The study was approved by the local 
ethics committee.
Patients were re-evaluated in our clinic every 
three months up to 36 months after the event (median 
follow-up 32 months; range 4−36) or when they expe-
rienced cardiovascular events (myocardial infarction, 
angina, stroke, transient ischemic attack, critical limb 
ischemia, need for percutaneous revascularization pro-
cedures or coronary artery by-pass).
Methods
Biochemical Measurements
Blood samples, collected within 72 hours of 
the ischemic event, were processed according to the 
recent recommendations regarding the appropriate 
specimen and preparation for laboratory evaluation of 
sCD40L18, 19). Thus, blood samples were anticoagu-
lated in Na citrate 3.8% (1:9 v:v), centrifuged at 2,000 
g for 10 minutes at 4℃. Supernatants were collected. 
Plasma was stored at －80℃ until analysis. Plasma 
CD40L and MCP-1 levels were measured by enzyme-
linked immunosorbent assay (R&D Systems, Minne-
apolis, Minnesota).
Statistical Analysis
Statistical analysis was performed by chi-square 
statistics, Pearson’s correlation coefficient t test for 
independent samples and by one-way analysis of vari-
ance with Bonferroni adjustment to assess differences 
among groups. When necessary, appropriate nonpara-
metric tests were used (Spearman correlation coeffi-
cient and Mann-Whitney U test). Because the distri-
bution of sCD40L and MCP-1 was skewed (Shapiro-
Wilk test) the concentration of these variables was 
also analyzed statistically by quartiles. Multiple linear 
regression analysis was performed to further quantify 
the relationship between MCP-1 (divided into quar-
tiles) and the possible explanatory factor. Specifically, 
the dependent variable, MCP-1, was regressed for 
sCD40L (divided into quartiles), age, SSS score, sex, 
TOAST group, HbA1c, arterial blood pressure, total 
cholesterol, BMI, diabetes duration, and previous vas-
cular events. The clinical relevance of parameters used 
to predict all endpoints (vascular events, such as myo-
cardial infarction, episodes of unstable angina, stroke, 
transient ischaemic attack, and critical limb ischemia) 
was estimated by univariate (log rank test) and multi-
variate (Cox proportional hazard model including 
variables that achieved statistical significance in uni-
variate analysis) analyses. Only p values lower than 0.05 
were regarded as significant. Data are presented as the 
mean (SD), or median (interquartile range) (SPSS by 
SPSS Inc. and EGRET by SERC city, state/country).
Results
According to the TOAST criteria, the etiology 
of stroke was large-artery atherosclerosis (LAA) in 36 
(40%) patients, cardioembolism (CE) in 13 (14%) 
patients, and lacunar stroke [small artery occlusion 
(SAO)] in 41 (46%) patients.
Patients and controls were comparable for age 
(72±10 vs 72±9, p=0.8989) and sex [males: 51 (57%) 
vs 26 (58%), p=0.90).
Diabetic patients with acute stroke had higher 
plasma CD40L [median (interquartile range): 1,252 
(813−2468) vs 456 (326−650) pg/mL p＜0.0001] and 
MCP-1 [210 (157−348) vs 135 (85−198) pg/mL, p＜
0.0001] than controls (Fig.1).
No significant differences in plasma CD40L or 
MCP-1 levels among different TOAST groups (p=  
0.486 and p=0.378, respectively, Fig.1 inside panels) 
were detected.
The SSS on admission showed the lowest values 
in cardioembolic stroke [median (interquartile range): 
22 (19−29)] as compared with LAA [37.5 (31−40)] or 
lacunar stroke [42 (37−42)] (p＜0.0001).
Among all patients, plasma MCP-1 directly 
correlated with sCD40L (Rho=0.69, p＜0.0001). 
Because the distribution of sCD40L (Shapiro-Wilk 
W=0.75815, p＜0.00001) and MCP-1 (Shapiro-Wilk 
W=0.87251, p＜0.0001) was skewed, the concentra-
tion of these variables was also analyzed statistically by 
quartiles.
Thus, multiple-linear regression analysis was per-
formed to further quantify the relationship between 
plasma sCD40L and MCP-1 and the other possible 
explanatory factors. Multiple regression analysis indi-
cated that only higher sCD40L quartiles (b=0.70, 
SE=0.08; p＜0.0001) and higher age (b=0.21, SE=  
0.08; p＜0.02) were associated with higher MCP-1 
quartiles, independently of SSS score, sex, TOAST 
group, HbA1c, diabetes duration, body mass index, 
systolic and diastolic blood pressure, total cholesterol, 
and previous vascular events. In fact, 17 out of 24 
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patients (71%) with MCP-1 in the upper quartile 
showed sCD40L in the upper quartile.
At discharge from the stroke unit, the SSS score 
showed a significantly improvement in all included 
patients (36.7±10.2 to 44.8±10.6, t=－12.73, median 
change=＋29%, p＜0.0001). Nevertheless, MCP-1, 
sCD40L plasma levels, and the other risk factors did 
not show any significant correlation with SSS improve-
ment.
Median follow-up was 24 months (12 to 36 
months). No patient was lost to follow-up. Three 
patients died of causes unrelated to vascular events 
(censored data). Forty-three (48%) patients experi-
enced vascular events (1 fatal and 4 nonfatal myocar-
dial infarctions, 9 episodes of unstable angina, 7 
strokes, 15 transient ischaemic attacks, 7 critical limb 
ischemia). No significant difference was observed in 
the rate of vascular events among patients with lacu-
nar vs non-lacunar stroke (Table 2). No difference in 
the ongoing treatment (aspirin and/or statins) was 
observed between patients who experienced a vascular 
event and those who did not, or among CD40L and 
MCP-1 quartiles.
Median values of plasma CD40L [2,324 (1,355−
3,310) vs 826 (670−1,147) pg/mL, p＜0.0001] and 
MCP-1 [327 (236−408) vs 161 (133−193) pg/mL, 
p＜0.0001] at the time of the inciting acute stroke 
were higher in those who experienced an event during 
follow-up than in those who remained event-free.
Univariate and multivariate analyses were per-
formed by the Cox proportional hazard model: the 
first step was performed by the log rank test, and the 
covariates found to be associated were included in 
the Cox regression model (Fig.2). Of the parameters 
listed in Table 2, only high sCD40L levels were 
entered in the Cox proportional hazard model. In fact, 
the presence of higher sCD40L values had an inde-
pendent prognostic value in predicting the recurrence 
of vascular events (hazard ratio=2.6, 95% confidence 
limits: 1.9−3.6, p＜0.001). In particular, 31 (72%) out 
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Fig.1. Monocyte chemoattractant protein-1 (MCP-1) and soluble CD40 
ligand (sCD40L) in control subjects and diabetic patients who experi-
enced stroke of non-lacunar and lacunar type (inside panel).
LAA= large-artery atherosclerosis (non-lacunar stroke), CE=cardioembolic (non-
lacunar stroke), SAO= small artery occlusion (lacunar stroke). Error bars represent 
minimum and maximum values, the heavy horizontal rules indicate median values, 
and the ends of the boxes indicate interquartile range. ＊Mann-Whitney U test
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of 43 patients who experienced an event during fol-
low-up had CD40L and MCP-1 in the third and 
fourth quartiles.
Discussion
Type 2 diabetes is characterized by persistent 
platelet activation20), responsible for increased plasma 
levels of CD40L in this setting9). CD40L released 
from platelets induces inflammatory responses in the 
endothelium21). Activated platelets stimulate MCP-1 
production from endothelial cells through enhanced 
Table 2. Variables showing prognostic significance by the log-
rank test and evaluated as prognostic indicators by 
cox model in the 90 patients
Variables
No. of
Patients
%
EndPoint
Log-Rank
Test
p value
Sex,
Females
Males
Age＊
＜72 yrs
＞72 yrs
TOAST
LAA
SAO
CE
Diabetes duration＊
≤8 yrs
＞8 yrs
HbA1c＊
＜7%
＞7%
BMI＊
≤31
＞31
Hypertension
No
Yes
Dyslipidemia
No
Yes
Previous ischemic event
No
Yes
Aspirin treatment
No
Yes
sCD40L
1st quartile
2nd quartile
3rd quartile
4th quartile
MCP-1
1st quartile
2nd quartile
3rd quartile
4th quartile
39
51
44
46
36
41
13
46
44
34
56
58
32
35
55
48
42
20
70
48
42
22
23
22
23
22
23
21
24
48.72
47.06
43.18
52.17
58.33
36.59
53.85
39.13
56.81
41.18
51.79
44.82
49.09
54.29
43.64
56.25
38.10
30.00
52.86
45.83
50.00
00.00
30.43
77.27
82.61
13.64
21.74
76.19
79.17
0.03
0.95
3.33
0.46
0.93
1.81
1.04
2.58
2.68
0.06
41.60
36.77
＞0.05
＞0.05
＞0.05
＞0.05
＞0.05
＞0.05
＞0.05
＞0.05
＞0.05
＞0.05
＜0.001
＜0.001
＊＞50th of the stroke population
TOAST=Trial of Org 10172 in Acute Stroke Treatment; LAA= large-
artery atherosclerosis; SAO= small artery occlusion; CE=cardioem-
bolism; HbA1c=Hemoglobin A1c; BMI=Body Mass Index; sCD40L=  
soluble CD40 ligand; MCP-1=Monocyte chemoattractant protein-1.
MCP-1=Q1
MCP-1=Q2
MCP-1=Q3
MCP-1=Q4P<0.001
P<0.001
sCD40L=Q1
sCD40L=Q2
sCD40L=Q3
sCD40L=Q4
Panel A
Panel B
2
Fig.2. Kaplan-Meier curves for patients grouped by their plasma 
levels of monocyte chemoattractant protein-1 (MCP-1) 
(Panel A) and soluble CD40 ligand (sCD40L) (Panel B).
Q=quartile. [MCP-1: Q1＜157, Q2＞157 and ＜210.5, Q3＞
210.5 and ＜348, Q4＞348 pg/mL] [sCD40L: Q1＜813, Q2＞
813 and ＜1,252, Q3＞1,252 and ＜2,468, Q4＞2,468 pg/mL]. 
＊Cox proportional hazard model.
MCP-1=Q1
- 2
MCP-1=Q3
MCP-1=Q4P<0.001
P<0.001
sCD40L=Q1
sCD40L=Q2
sCD40L=Q3
sCD40L=Q4
Panel A
Panel B
2
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CD40L shedding10) and this seems particularly rele-
vant in type 2 diabetes12, 22). MCP-1 plays an impor-
tant role in the early phase of atherosclerosis by initi-
ating monocyte recruitment to the vessel wall23); thus, 
platelet-derived CD40L can trigger the recruitment of 
monocytes or promote their differentiation into mac-
rophages21), inducing MCP-1 release from the endo-
thelium. Upregulation of MCP-1 and sCD40L has 
been found in patients with acute cerebral ischemia13). 
Platelets contribute to enhanced MCP-1 levels in 
patients with chronic heart failure10). In patients with 
acute coronary syndromes24), as well as in type 2 dia-
betes12), an elevated baseline level of MCP-1 is associ-
ated with an increased risk for cardiovascular death.
The evidence for a role of sCD40L in cardiovas-
cular disease is even greater, suggesting that CD40L 
levels are a prominent candidate for early detection in 
cardiac disease25, 26). Activation of the CD40-CD40L 
dyad has been observed in atherosclerosis-related dis-
eases19) and CD40L levels may predict cardiovascular 
risk in women27). Acute cerebral ischemia is associated 
with persistent thromboxane-dependent platelet acti-
vation in vivo5). Up-regulation of CD40-CD40L has 
been also shown in patients with acute cerebral isch-
emia13) and high levels of sCD40L may predict the risk 
of cardiovascular events both in high-risk plaques28) 
and in asymptomatic low-grade carotid stenosis29).
This study demonstrates for the first time that 
early elevation of plasma CD40L and MCP-1 after an 
acute stroke is associated with long-term risk of non-
fatal vascular events in a large group of patients with 
diabetes and acute stroke. On multiple-linear regres-
sion analysis, all patients with MCP-1 levels in the 
third/fourth quartiles showed sCD40L values in the 
two highest quartiles. Moreover, we demonstrated the 
potential prognostic value of an elevated CD40L level 
in stroke patients during 2 years of follow-up, thus 
suggesting that CD40L shedding acting at the inter-
face between endothelial cells and platelets, and 
thereby triggering both inflammation and platelet acti-
vation, is an early event upstream of vascular events. 
These findings strongly suggest that enhanced platelet-
derived mediators of the inflammatory response may 
predict the risk of cardiovascular events after stroke.
The age-standardized incidence rates for the 
European population (per 100 000) regarding isch-
emic stroke subtypes were as follows: cardioembolism, 
30.2; small-artery occlusion, 25.8; and large-artery 
atherosclerosis, 15.3. Two years after onset, patients in 
the small-artery occlusion subgroup were 3 times more 
likely to be alive than those with cardioembolism15). 
We found that sCD40L and MCP-1 are similarly 
up-regulated among nonlacunar and lacunar strokes, 
in agreement with a recent meta-analysis showing a 
similar risk of cardiac outcome in longer term surveil-
lance between the two subtypes6).
In conclusion, up-regulation of inflammatory 
molecules, such as CD40L and MCP-1, is involved in 
the advanced stage of diabetic cerebro-vascular dis-
ease. Elevated CD40L levels are associated with an 
increased risk of recurrence of cardiovascular events. 
Statins are able to downregulate both soluble MCP-1 
and CD40L30, 31) and a number of additional drugs, 
including glitazones, antioxidant and antiplatelets, 
have been shown to favorably modulate sCD40L32). 
Thus, both CD40L and MCP-1 are attractive as sur-
rogate biomarkers and merit further study as potential 
therapeutic targets in diabetic acute cerebral ischemia. 
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